OKYO Pharma is scheduled to present data on their dry eye drug at an important conference.

OKYO Pharma Ltd (LSE: OKYO, NASDAQ: OKYO), a biopharmaceutical company focused on ophthalmology, is set to present two papers on their treatment for dry eye disease (DED), OK-101, at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, California, from May 5-8.

The presentations will be delivered by Dr. Pedram Hamrah, a renowned expert on DED and corneal neuropathic pain, who serves as the co-director of the Cornea Service and director of the Center for Translational Ocular Immunology at the New England Eye Center at Tufts Medical Center.

The papers will focus on pre-clinical and animal model data, demonstrating the effectiveness of OK-101 in treating DED and Neuropathic Corneal Pain (NCP). OK-101 is a potential breakthrough treatment aimed at addressing the significant unmet need in the multi-billion-dollar market for DED.

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Weekly Newsletter

Sign up to receive exclusive stock market content in your inbox, once a week.

We don’t spam! Read our privacy policy for more info.